Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Saurabh Sethi

General GI · Oja Health

View

Dr. Wendi LeBrett

General GI · ModernGut

View

Dr. Treta Purohit

General GI · Oshi Health

View

Dr. Rushabh Modi

General GI · Kaiser Permanente

View

Dr. Brennan Spiegel

General GI · Cedars-Sinai

View

Dr. Mark Pochapin

General GI · NYU Langone

View

Dr. Amy Oxentenko

General GI · Mayo Clinic College of Medicine

View

Dr. Edward Sheen

General GI · L.A. Care

View

Dr. Sara Horst

IBD · Vanderbilt

View

Dr. Nneka Ufere

Liver Transplant · MGH

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    DSDr. Debra Silberg

    Dr. Debra Silberg

    Gastroenterology · General Gastroenterology
    Beyond Celiac
    debras

    Research

    Delay in Celiac Disease Diagnosis Among Patients with High-Risk Screening Conditions: Results from a United States Claims Database

    2025

    Via Journal of Clinical Medicine

    Research

    Gaps and Disparities in Celiac Disease Screening: A Nationwide Analysis of a High-Risk Pediatric Population

    2025

    Via Digestive Diseases and Sciences

    Research

    Randomized Controlled Trials in Celiac Disease: Expressing the Patient's Voice

    2024

    Via Gastroenterology

    Research

    Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease

    2019

    Via Gastroenterology

    Research

    Absorption, Distribution, Metabolism, and Excretion of [¹⁴C]-Volixibat in Healthy Men: Phase 1 Open-Label Study

    2018

    Via European Journal of Drug Metabolism and Pharmacokinetics

    Research

    A Randomised, Double-Blind, Placebo-Controlled Phase 1 Study of the Safety, Tolerability and Pharmacodynamics of Volixibat in Overweight and Obese but Otherwise Healthy Adults: Implications for Treatment of Non-Alcoholic Steatohepatitis

    2018

    Via BMC Pharmacology & Toxicology

    Research

    PRISM, a Patient-Reported Outcome Instrument, Accurately Measures Symptom Change in Refractory Gastroesophageal Reflux Disease

    2017

    Via Digestive Diseases and Sciences

    Research

    Development of the Pediatric Daily Ulcerative Colitis Signs and Symptoms Scale (DUCS): Qualitative Research Findings

    2017

    Via BMC Research Notes

    Research

    Development of a Symptom-Based Patient-Reported Outcome Instrument for Functional Dyspepsia: A Preliminary Conceptual Model and an Evaluation of the Adequacy of Existing Instruments

    2016

    Via The Patient

    Research

    Dose-Dependent Effects of Lesogaberan on Reflux Measures in Patients with Refractory Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled Study

    2014

    Via BMC Gastroenterology

    Research

    Esophageal Mucosal Breaks in Gastroesophageal Reflux Disease Partially Responsive to Proton Pump Inhibitor Therapy

    2013

    Via The American Journal of Gastroenterology

    Research

    Obesity Does Not Affect Treatment Outcomes with Proton Pump Inhibitors

    2013

    Via Journal of Clinical Gastroenterology

    Research

    Effect of Food on the Bioavailability of Lesogaberan Given as an Oral Solution or as Modified-Release Capsules in Healthy Male Volunteers

    2012

    Via International Journal of Clinical Pharmacology and Therapeutics

    Research

    Efficacy and Safety of Lesogaberan in Gastro-Oesophageal Reflux Disease: A Randomised Controlled Trial

    2012

    Via Gut

    Research

    Pretreatment Data Is Highly Predictive of Liver Chemistry Signals in Clinical Trials

    2012

    Via Drug Design, Development and Therapy